Key result
Long-term carvedilol fails to reduce major cardiovascular events after primary PCI for STEMI.
Why the study?
Does long-term carvedilol therapy reduce the composite of all-cause death, myocardial infarction, hospitalization for heart failure, and hospitalization for acute coronary syndrome in uncomplicated STEMI patients treated with primary PCI?
RCT (n=801)
Open-label
1-to-1 stochastic minimization algorithm
Yes
Does long-term carvedilol therapy reduce the composite of all-cause death, myocardial infarction, hospitalization for heart failure, and hospitalization for acute coronary syndrome in uncomplicated STEMI patients treated with primary PCI?
Answers are grounded in this paper and cite their sources.
Long-term carvedilol therapy did not improve clinical outcomes in uncomplicated STEMI patients with preserved LVEF treated with primary PCI, challenging current guideline recommendations for routine beta-blocker use in this population.
BACKGROUND: Despite its recommendation by the current guidelines, the role of long-term oral beta-blocker therapy has never been evaluated by randomized trials in uncomplicated ST-segment elevation myocardial infarction (STEMI) patients without heart failure, left ventricular dysfunction or ventricular arrhythmia who underwent primary percutaneous coronary intervention (PCI). METHODS AND RESULTS: In a multi-center, open-label, randomized controlled trial, STEMI patients with successful primary PCI within 24 hours from the onset and with left ventricular ejection fraction (LVEF) ≥40% were randomly assigned in a 1-to-1 fashion either to the carvedilol group or to the no beta-blocker group within 7 days after primary PCI. The primary endpoint is a composite of all-cause death, myocardial infarction, hospitalization for heart failure, and hospitalization for acute coronary syndrome. Between August 2010 and May 2014, 801 patients were randomly assigned to the carvedilol group (N = 399) or the no beta-blocker group (N = 402) at 67 centers in Japan. The carvedilol dose was up-titrated from 3.4±2.1 mg at baseline to 6.3±4.3 mg at 1-year. During median follow-up of 3.9 years with 96.4% follow-up, the cumulative 3-year incidences of both the primary endpoint and any coronary revascularization were not significantly different between the carvedilol and no beta-blocker groups (6.8% and 7.9%, P = 0.20, and 20.3% and 17.7%, P = 0.65, respectively). There also was no significant difference in LVEF at 1-year between the 2 groups (60.9±8.4% and 59.6±8.8%, P = 0.06). CONCLUSION: Long-term carvedilol therapy added on the contemporary evidence-based medications did not seem beneficial in selected STEMI patients treated with primary PCI. TRIAL REGISTRATION: CAPITAL-RCT (Carvedilol Post-Intervention Long-Term Administration in Large-scale Randomized Controlled Trial) ClinicalTrials.gov.number, NCT 01155635.
No takes yet. Share an insight, caveat, or question.
Watanabe et al. (2018) conducted an RCT in ST-segment elevation myocardial infarction (STEMI) (n=801). Carvedilol vs. No beta-blocker was evaluated on Composite of all-cause death, myocardial infarction, hospitalization for heart failure, and hospitalization for acute coronary syndrome (HR 0.75, 95% CI 0.47-1.16, p=0.20). Long-term carvedilol therapy did not reduce the composite of all-cause death, myocardial infarction, or hospitalization for heart failure or acute coronary syndrome compared to no beta-blocker in STEMI patients treated with primary PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: